Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

References

• Rigopoulos D, Stathopoulou A, Gregoriou S. Small molecules and biologics in the treatment of nail psoriasis. Skin Appendage Disord. 2020;6(3):134–141.
   PubMed Web of Science ®Google Scholar
• Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131–135.
   PubMedGoogle Scholar
• Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis. 2017;7:51–63.
   PubMed Web of Science ®Google Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27.
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Starace M, Bruni F, et al. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol. 2019;99(6):516–523.
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580–585.
   PubMed Web of Science ®Google Scholar
• Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020:1–5.DOI:10.1080/09546634.2020.1749546
   Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2020.DOI:10.1111/bjd.19262
   Web of Science ®Google Scholar
• Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224–231.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020;79(10):1310–1319.
   PubMed Web of Science ®Google Scholar
• Wasel N, Thaçi D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther. 2020;10(4):663–670.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, et al. IXORA-R study group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomised, double-blinded trial. Br J Dermatol. 2020.DOI:10.1111/bjd.19509
   Web of Science ®Google Scholar
• Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78(1):90–99.
   PubMed Web of Science ®Google Scholar
• Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154(6):676–683.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131.
   PubMed Web of Science ®Google Scholar
• Busard CI, Nolte JYC, Pasch MC, et al. Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review. Br J Dermatol. 2018;178(3):640–649.
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Patsatsi A, Sotiriadis D. Biologic agents in nail psoriasis: efficacy data and considerations. Expert Opin Biol Ther. 2013;13(12):1707–1714.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: adalimumab (Humira®) summary of product characteristics [Internet]. Amsterdam (The Netherlands): EMA; 2020 [cited 2020 October 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency: brodalumab (Kyntheum®) summary of product characteristics [Internet]. Amsterdam (The Netherlands): EMA; 2020 [cited 2020 October 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency: guselkumab (Tremfya®) summary of product characteristics [Internet]. Amsterdam (The Netherlands): EMA; 2020 [cited 2020 October 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency: infliximab (Remicade®) summary of product characteristics [Internet]. Amsterdam (The Netherlands): EMA; 2020 [cited 2020 October 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency: ixekizumab (Taltz®) summary of product characteristics [Internet]. Amsterdam (The Netherlands): EMA; 2020 [cited 2020 October 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency: ustekinumab (Stelara®) summary of product characteristics [Internet]. Amsterdam (The Netherlands): EMA; 2020 [cited 2020 October 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf
   Google Scholar
• Reich K, Kristensen LE, Smith SD, et al. Ixekizumab shows early and sustained resolution of nail psoriasis in patients with psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H). Poster FC02.06-846 presented at: 29th European Academy of Dermatology and Venereology (EADV) Congress; 2020 Oct 28‒November 1; Vienna, Austria.
   Google Scholar
• Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080–1087.
   PubMed Web of Science ®Google Scholar
• Szebényi J, Gede N, Hegyi P, et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: a network meta-analysis. Acta Derm Venereol. 2020;100(18):adv00318.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:CD011535.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Ash Z, Dickie L, et al. The early phase of psoriatic arthritis. Ann Rheum Dis. 2011;70(1):i71–i76.
   PubMed Web of Science ®Google Scholar
• Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153–166.
   PubMed Web of Science ®Google Scholar
• Rusk AM, Fleischer AB. Jr. In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity. J Dermatolog Treat. 2020:1–4.DOI:10.1080/09546634.2020.1720578
   Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):15–21.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008;159(2):453–456.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Holko P, Moćko P, et al. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018;38(2):189–201.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Nash P, Ritchlin C, et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. J Comp Eff Res. 2018;7(11):1107–1123.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar